Free tool
FDA Approval Tracker
Last checked: Nov 20, 2026Latest source record: Jul 28, 2026Drugs@FDA last updated: Nov 18, 2026Methods & limitations
Matching approvals
14
2023 to 2026
Breakthrough
3
Accelerated
1
Priority review
6
Orphan
4
By year
NDAs and BLAs matching the filters.
- NDA
- BLA
View as table
| Year | NDA | BLA |
|---|---|---|
| 2023 | 3 | 1 |
| 2024 | 3 | 0 |
| 2025 | 4 | 0 |
| 2026 | 2 | 1 |
14 approvals
Newest first. Hover a badge for what it means.
- Gwyn Lo (Ethinyl Estradiol, Norelgestromin) · Viatris SpecialtyJul 28, 2026Original approval · NDA 219990Approval letter
- Lumvoa (Veligrotug-Vvze) · Viridian Therapeutics INCJun 26, 2026
To treat thyroid eye disease
- Veppanu (Vepdegestrant) · Rigel PharmsMay 1, 2026
To treat estrogen receptor-positive, human epidermal growth factor receptor 2-negative, ESR1-mutated advanced or metastatic breast cancer with disease progression following at least one line of endocrine therapy
- Lynkuet (Elinzanetant) · Bayer HlthcareOct 24, 2025
To treat moderate-to-severe vasomotor symptoms due to menopause
- Inluriyo (Imlunestrant Tosylate) · Eli Lilly and COSep 25, 2025
To treat estrogen receptor-positive, human epidermal growth factor receptor 2-negative, estrogen receptor-1-mutated advanced or metastatic breast cancer with disease progression following at least one line of endocrine therapy
- Palsonify (Paltusotine Hydrochloride) · CrineticsSep 25, 2025
To treat acromegaly in adults who had an inadequate response to surgery and/or for whom surgery is not an option
- Miudella (Copper) · Sebela Womens HlthFeb 24, 2025Original approval · NDA 218201Approval letter
- Crenessity (Crinecerfont) · NeurocrineDec 13, 2024
To treat classic congenital adrenal hyperplasia
- Yorvipath (Palopegteriparatide) · Ascendis Pharma BoneAug 9, 2024
To treat hypoparathyroidism
- Rezdiffra (Resmetirom) · MadrigalMar 14, 2024Original approval · NDA 217785NovelBreakthrough therapyAccelerated approvalPriority reviewApproval letter
To treat noncirrhotic non-alcoholic steatohepatitis with moderate to advanced liver scarring
- Ngenla (Somatrogon-Ghla) · Pfizer Ireland PharmaceuticalsJun 27, 2023
To treat growth failure due to inadequate secretion of endogenous growth hormone
- Veozah (Fezolinetant) · AstellasMay 12, 2023
To treat moderate to severe hot flashes caused by menopause
- Adrenalin (Epinephrine) · Ph HealthApr 21, 2023Original approval · NDA 215875Approval letter
- Orserdu (Elacestrant Hydrochloride) · Stemline TherapJan 27, 2023
To treat estrogen receptor-positive, human epidermal growth factor receptor 2-negative, ESR1-mutated, advanced or metastatic breast cancer with disease progression following at least one line of endocrine therapy
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.